Moderna Earnings Estimate

MRNA
 Stock
  

USD 142.85  0.04  0.028%   

Many public companies, such as Moderna, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Moderna's earnings estimates, investors can diagnose different trends across Moderna's analyst sentiment over time as well as compare current estimates against different timeframes.
Moderna is projected to generate 26.32 in earnings per share on the 31st of December 2021. Moderna earnings estimates module stress-tests analyst consensus about projected Moderna EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Additionally, see Stocks Correlation.
  
Refresh
The current year Gross Profit is expected to grow to about 17.1 B. The current year Profit Margin is expected to grow to 0.71

Moderna Earnings Estimation Breakdown

Calculation of earning per share of Moderna is based on official Zacks consensus of 7 analysts regarding Moderna future annual earnings. Given the historical accuracy of 78.33%, the future earnings per share of Moderna is estimated to be 26.32 with the lowest and highest values of 22.25 and 28.11, respectively. Please note that this consensus of annual earnings estimates for Moderna is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS 16.69
22.25
Lowest
Expected EPS 26.32
28.11
Highest

Moderna Earnings Projection Consensus

Suppose the current estimates of Moderna's value are higher than the current market price of the Moderna stock. In this case, investors may conclude that Moderna is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Moderna's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

7

78.33%

16.69

26.32

Moderna Earnings History

Earnings estimate consensus by Moderna analysts from Wall Street is used by the market to judge Moderna's stock performance. The investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Moderna's upcoming profit reports and earnings-per-share forecasts but also compare them to our different valuation methods.

Moderna Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

4.31 Billion

Share
The current year Accumulated Retained Earnings Deficit is expected to grow to about 10.7 B. The current year Earning Before Interest and Taxes EBIT is expected to grow to about 14.3 B As of June 30, 2022, Weighted Average Shares is expected to decline to about 339.6 M. In addition to that, Weighted Average Shares Diluted is expected to decline to about 357 M.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Moderna's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Moderna in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
145.15149.50153.85
Details
Intrinsic
Valuation
LowReal ValueHigh
132.24174.40178.75
Details
Naive
Forecast
LowNext ValueHigh
154.65158.99163.34
Details
13 Analysts
Consensus
LowTarget PriceHigh
86.00257.23506.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Moderna. Your research has to be compared to or analyzed against Moderna's peers to derive any actionable benefits. When done correctly, Moderna's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Moderna.
Note that many institutional investors and large investment bankers can move markets due to the volume of Moderna assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Moderna. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Moderna stock price in the short term.

Moderna Earnings per Share Projection vs Actual

Actual Earning per Share of Moderna refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Moderna predict the company's earnings will be in the future. The higher the earnings per share of Moderna, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Moderna Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Moderna, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Moderna should always be considered in relation to other companies to make a more educated investment decision.

Moderna Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Moderna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-04
2022-03-315.218.583.3764 
2022-02-24
2021-12-319.911.291.3914 
2021-11-04
2021-09-309.37847.7-1.678417 
2021-08-05
2021-06-305.85646.460.603610 
2021-05-06
2021-03-312.46692.840.373115 
2021-02-25
2020-12-31-0.364-0.69-0.32689 
2020-10-29
2020-09-30-0.3678-0.59-0.222260 
2020-08-05
2020-06-30-0.363-0.310.05314 
2020-05-07
2020-03-31-0.3638-0.350.0138
2020-02-26
2019-12-31-0.4215-0.370.051512 
2019-11-06
2019-09-30-0.4386-0.370.068615 
2019-08-07
2019-06-30-0.4499-0.410.0399
2019-05-08
2019-03-31-0.3645-0.4-0.0355
2019-03-06
2018-12-31-0.3505-0.44-0.089525 
2018-06-30
2018-06-30None-0.29None

About Moderna Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Moderna earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Moderna estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Moderna fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit10 B10.7 B
Earning Before Interest and Taxes EBIT13.3 B14.3 B
Earnings per Basic Share 30.31  32.71 
Earnings per Diluted Share 28.29  30.52 
Price to Earnings Ratio 8.38  9.04 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA13.5 B14.6 B
Earnings before Tax13.3 B14.3 B
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.

Moderna Investors Sentiment

The influence of Moderna's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moderna. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Moderna Implied Volatility

    
  90.95  
Moderna's implied volatility exposes the market's sentiment of Moderna stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Moderna's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Moderna stock will not fluctuate a lot when Moderna's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moderna in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moderna's short interest history, or implied volatility extrapolated from Moderna options trading.

Current Sentiment - MRNA

Moderna Investor Sentiment

Most of Macroaxis users are now bullish on Moderna. What is your trading attitude regarding investing in Moderna? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
56.8 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.